<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04569604</url>
  </required_header>
  <id_info>
    <org_study_id>#11102018</org_study_id>
    <secondary_id>1-10-72-304-18</secondary_id>
    <nct_id>NCT04569604</nct_id>
  </id_info>
  <brief_title>QoL and Cognitive Function in Patients With Hypoparathyroidism</brief_title>
  <acronym>MR-hypoPT</acronym>
  <official_title>Impaired Quality of Life and Cognitive Function in Patients With Hypoparathyroidism Might be Explained by Disturbed Capillary Flow Patterns in the Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoparathyroidism (HypoPT) is a disease with inadequate production of parathyroid hormone&#xD;
      (PTH) from the parathyroid glands leading to hypocalcemia. The most common form is&#xD;
      postsurgical HypoPT due to neck surgery resulting in removed or damaged parathyroid glands.&#xD;
&#xD;
      HypoPT is a complex disease with a reduced Quality of life, mild cognitive impairment and in&#xD;
      some patients have brain calcifications.&#xD;
&#xD;
      The aim of the present study is to investigate the cognitive function in patients with&#xD;
      postsurgical and non-surgical (HypoPT) by neuropsychological assessments and magnetic&#xD;
      resonance imaging (MRI).&#xD;
&#xD;
      The investigators will apply a contrast-enhanced MRI based method to HypoPT patients and age-&#xD;
      and gender matched controls to examine whether capillary dysfunction can be detected, and&#xD;
      whether symptom severity across patients correlates with the degree of capillary dysfunction&#xD;
      in certain brain regions. To our knowledge there have been no previous studies on cognitive&#xD;
      impairment and its origin in patients with HypoPT. The investigators hypothesize that the&#xD;
      symptoms of HypoPT patients represent various degrees of capillary dysfunction, which&#xD;
      interfere with their brain function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypoparathyroidism (HypoPT) is a disease with inadequate production of parathyroid hormone&#xD;
      (PTH) from the parathyroid glands leading to hypocalcemia. The most common form is&#xD;
      postsurgical HypoPT due to neck surgery resulting in removed or damaged parathyroid glands.&#xD;
      Postsurgical HypoPT has a prevalence of 22/100,000 inhabitants in Denmark. Nonsurgical HypoPT&#xD;
      is most often caused by mutations in different genes or on an autoimmune basis, the&#xD;
      prevalence of nonsurgical HypoPT is 2.3/100,000 inhabitants in Denmark. If the gene mutation&#xD;
      is within the GNAS gene or upstream of the GNAS complex locus it causes PseudoHypoPT (PHP),&#xD;
      which is characterized by target organ resistance to PTH, also resulting in hypocalcaemia and&#xD;
      hyperphosphatemia as in post- and nonsurgical HypoPT, but in this case with high or normal&#xD;
      levels of plasma PTH. PHP is a very rare disease with a prevalence of 1/100,000 inhabitants&#xD;
      in Denmark.&#xD;
&#xD;
      Others and the investigators have previously shown that HypoPT and/or hypocalcemia may affect&#xD;
      quality of life (QoL). In most cases, severe symptoms and findings diminished or disappeared&#xD;
      when plasma calcium levels are restored to normal, but as some of the above mentioned studies&#xD;
      have shown, the reduced QoL is still present despite normal calcium levels. Symptoms are&#xD;
      describes as minor cognitive impairment (MCI), with confusion, forgetfulness, and lack of&#xD;
      focus and mental clarity. Another important finding in some of the patients with HypoPT is&#xD;
      calcifications of the basal ganglia as described in several case reports, the knowledge of&#xD;
      the origin and importance of these is so far limited. Patients with PHP have previously been&#xD;
      described to have a higher risk of calcifications of the lens and subcutaneous&#xD;
      calcifications, and therefore might also be at higher risk of calcifications in the brain.&#xD;
&#xD;
      The oxygen availability in brain tissue is traditionally thought to depend on regional&#xD;
      cerebral blood flow (CBF). Accordingly, brain oxygenation is only expected to impair brain&#xD;
      function in cases where CBF is critically reduced, cerebral ischemia. This paradigm was&#xD;
      recently shown to be in error: While CBF determines the oxygen supply, the microscopic&#xD;
      distribution of blood flows across the capillary bed determines the extent to which this&#xD;
      oxygen can be extracted by the tissue. In fact, capillary flow patterns can become so&#xD;
      disturbed that the metabolic needs of brain function and survival can no longer be met -&#xD;
      although CBF remains inconspicuous. Capillary dysfunction denotes this overlooked source of&#xD;
      hypoxia: A state in which capillary flow patterns cannot homogenize, giving rise to tissue&#xD;
      hypoxia, oxidative stress, local inflammation, and - if severe - long-term neurodegeneration.&#xD;
      The investigators hypothesize that the symptoms of HypoPT patients represent various degrees&#xD;
      of capillary dysfunction, which interfere with their brain function.&#xD;
&#xD;
      The purpose of the study is to investigate whether HypoPT patients are affected by capillary&#xD;
      dysfunction, a condition in which capillary flow disturbances interfere with brain&#xD;
      oxygenation.&#xD;
&#xD;
      The hypothesis derives from findings that cerebral calcifications similar to those found in&#xD;
      HypoPT are observed in familial idiopathic basal ganglia calcification (IBGC), which is a&#xD;
      disease of cerebral pericytes. Pericytes are localized in the basement membrane of&#xD;
      capillaries, where they maintain blood brain barrier (BBB) function and - in close&#xD;
      interaction with endothelial cells - basement membrane and capillary wall integrity. They are&#xD;
      contractile and take part in blood flow regulation. They control the trafficking of immune&#xD;
      cells across the vessel wall and possess stem/progenitor cell functions. As such, they play a&#xD;
      key role in tissue repair, scarring, and fibrosis, and along with endothelial cells, they&#xD;
      seemingly have the potential to become bone-forming cells.&#xD;
&#xD;
      Pericytes (now referred to as 'mural cells') are characterized by several membrane proteins,&#xD;
      one of which (SLC9A3R1 - solute carrier family 9, isoform A3, regulatory factor 1, also known&#xD;
      as EBP50, NHERF) binds to parathyroid hormone 1 receptor (PTH1R) on one hand, and to plasma&#xD;
      derived growth factor (PDGF) receptor β (PDGFβ) on the other, potentiating its activity. The&#xD;
      physiological role of these receptors is poorly understood. Receptors for PTH and Parathyroid&#xD;
      hormone-related protein (PTH-rP) have been observed in both pericytes and smooth muscle cells&#xD;
      of various tissue types, while PTH-rP is expressed in the endothelium, acting as a&#xD;
      vasodilator. There is hence reason to believe that the function of capillary pericytes - and&#xD;
      hence capillary flow patterns - could be altered in HypoPT.&#xD;
&#xD;
      The investigators have developed a contrast-enhanced, magnetic resonance imaging (MRI) based&#xD;
      method to detect disturbances in microvascular flow patterns in the human brain and&#xD;
      demonstrated that knowledge of these flow patterns - as indexed by the capillary transit-time&#xD;
      heterogeneity (CTH) - allow us to better predict oxygen extraction efficacy as determined by&#xD;
      a gold-standard positron emission tomography (PET). The investigators have now found abnormal&#xD;
      microvascular flow patterns in patients with Alzheimer's disease (AD) or mild cognitive&#xD;
      impairment (MCI) compared to healthy, age-matched controls without cardiovascular risk&#xD;
      factors, and demonstrated that the degree of capillary dysfunction correlated with their&#xD;
      cognitive impairment. The investigators found a similar correlation in another AD patient&#xD;
      cohort, and most recently detected capillary dysfunction in patients with late-onset&#xD;
      depression compared to controls. In view of these findings, and the similarity between the&#xD;
      symptomatology of HypoPT and depression, the investigators now propose to apply our MRI&#xD;
      method to HypoPT patients and age- and gender matched controls to examine whether capillary&#xD;
      dysfunction can be detected, and whether symptom severity across patients correlates with the&#xD;
      degree of capillary dysfunction in certain brain regions.&#xD;
&#xD;
      The aim is to investigate the cognitive function in patients with postsurgical, non-surgical&#xD;
      and pseudoHypoPT by neuropsychological assessments and MRI. The contrast-enhanced MRI based&#xD;
      method will be applied to HypoPT patients and age- and gender matched controls to examine&#xD;
      whether capillary dysfunction can be detected, and whether symptom severity across patients&#xD;
      correlates with the degree of capillary dysfunction in certain brain regions.&#xD;
&#xD;
      The investigators hypothesize that the symptoms of HypoPT patients represent various degrees&#xD;
      of capillary dysfunction, which interfere with their brain function.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      MRI scans: The investigators plan to acquire the following MRI sequences:&#xD;
&#xD;
        1. Dynamic susceptibility contrast perfusion MRI will be applied for measurement of&#xD;
           capillary function and regional blood flow and volume as estimated by our by parametric&#xD;
           approach.&#xD;
&#xD;
        2. For further characterization of the microcirculation, resting state functional MRI will&#xD;
           be acquired. This sequence can be acquired in combination with the perfusion scan and&#xD;
           thus requires very little extra scanning time.&#xD;
&#xD;
        3. Fluid attenuated inversion recovery (FLAIR) images will be acquired for estimation of&#xD;
           white matter hyperintensities (WMH) and possible subcortical infarcts or lacunas.&#xD;
&#xD;
        4. A fast diffusion kurtosis imaging (DKI) sequence will be applied for estimation of&#xD;
           microstructural integrity of gray and white matter (e.g. dendrite density and white&#xD;
           matter tract integrity).&#xD;
&#xD;
        5. T1-weighted MRI will be utilized for accurate morphological characterization of cerebral&#xD;
           structures, such as hippocampus, basal ganglia, cortex and major tracts. In addition,&#xD;
           the high-resolution images enable accurate mapping of the functional data (perfusion,&#xD;
           fMRI, DKI).&#xD;
&#xD;
      Neuropsychological testing (NPT): The standard neuropsychological test battery consists of&#xD;
      validated tests to assess cognitive domains including verbal and visual memory, attention,&#xD;
      language, visuospatial and executive functioning.&#xD;
&#xD;
      Cognitive batteries: Cogstate battery for assessing cognitive function in adults with mild&#xD;
      cognitive impairment (MCI). The tests used are D-KEFS: TrailMaking A and B, Verbal Fluency&#xD;
      Test, and Color-Word Interference Test. The WAIS-IV: Coding, Symbol search, Digit span, and&#xD;
      Arithmetic. The BVMT-R: delayed recall and total learning. Lastly the RAVLT: delayed recall&#xD;
      and total learning.&#xD;
&#xD;
      Questionnaires: SF36v2, WHO-5 well-being index, Symptom questionnaire, and a general&#xD;
      questionnaire on background information, medication and diet, and HPQ28.&#xD;
&#xD;
      Biochemistry: Ionized calcium, PTH, phosphate, magnesium, eGFR, creatinine, High sensitive&#xD;
      CRP, 25-hydroxyvitamin D, calcitriol, and white blood cell count. Neuroinflammation and&#xD;
      systemic inflammatory markers (pro-inflammatory cytokines), and 24-hr urine.&#xD;
&#xD;
      Statistical Analysis Plan: Group difference will be examined using student T test for&#xD;
      continuous variables and Pearsons X^2 test for categorical variables. Statistical maps of&#xD;
      differences in perfusion parameters between patients and controls will be calculated at each&#xD;
      surface vertex using a vertex specific general linear model with cortical thickness, white&#xD;
      matter hyperintensity load ((WMHL) given as percentage white matter hyperintensities volume&#xD;
      of whole brain volume)), age, and gender as covariates. The investigators will add cortical&#xD;
      thickness as covariate to account for any systematic effects of cortical thickness on the&#xD;
      perfusion measurements, such as partial volume effects. All statistical maps will be&#xD;
      thresholded at p=0.05 (uncorrected and corrected). All statistical tests for the MRI scans&#xD;
      are carried out using R version 3.2.2 (The R Foundation for Statistical Computing) and SPM12&#xD;
      (Wellcome Trust Centre for Neuroimaging) running on Matlab R2016a (MathWorks Inc). Other&#xD;
      statistical test will be carried out by SPSS 24 (IBM, USA) Justification for sample size: In&#xD;
      a previous study by Eskildsen et al. the contrast-enhanced MRI based method has been applied&#xD;
      to 18 patients with Alzheimer's disease or MCI compared to 19 healthy, age-matched controls&#xD;
      without cardiovascular risk factors and it demonstrated that the degree of capillary&#xD;
      dysfunction correlated with their cognitive impairment. The investigators found a similar&#xD;
      correlation in another patient cohort with Alzheimer's disease, and most recently detected&#xD;
      capillary dysfunction in patients with late-onset depression compared to controls. Taking the&#xD;
      above mentioned results and the sizes of the cohorts in consideration, the investigators have&#xD;
      estimated that our sample size is enough to show if there is a correlation between cognitive&#xD;
      impairment measured by neuropsychological assessment and capillary transit time&#xD;
      heterogeneity.&#xD;
&#xD;
      Safety and ethnical evaluations: The investigators will follow the standard operating&#xD;
      procedures regarding contrast enhanced MRI scans. Peripheral venous catheter will be used for&#xD;
      administration of PET tracers and MRI contrast. It can result in mild local pain and a&#xD;
      hematoma. The risk of infection is negligible. There are no known risks (neither short- nor&#xD;
      long-term) related to MRI. Gadolinium-chelate (Gd) contrast is used. The standard dose of&#xD;
      gadolinium (Gd)-containing MRI-contrast is 0.1 mmol/kg, but in this study there will be used&#xD;
      up to 0.3 mmol/kg.&#xD;
&#xD;
      Perspectives: If successful and study findings provides a basis for improved understanding of&#xD;
      cognitive symptoms in HypoPT, further investigations on effects of PTH replacement therapy on&#xD;
      investigated indices should be considered. A future project could be performing the MRI scan&#xD;
      before and after injection of PTH to determine whether a change in capillary transit time&#xD;
      heterogeneity could be detected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Capillary transit time heterogeneity</measure>
    <time_frame>MRI scan performed at baseline, no follow-up up. It takes 1 hour to perform</time_frame>
    <description>Capillary transit time heterogeneity is measured by MRI scans</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Index 1: Processing speed</measure>
    <time_frame>Neuropsychological tests are performed immediately before or immediately after the MRI scan and scheduled to take 1½ hours.</time_frame>
    <description>Index 1 consist of the following tests&#xD;
Coding (WAIS-IV) scaled score&#xD;
Symbol search (WIAS-IV) scaled score&#xD;
A composit score from the above tests will be calculated and compared to the control group and normative data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index 2: Working memory</measure>
    <time_frame>Neuropsychological tests are performed immediately before or immediately after the MRI scan and scheduled to take 1½ hours.</time_frame>
    <description>Index 2 consist of the following tests&#xD;
Digit span (WAIS-IV) scaled score&#xD;
Arithmetic (WAIS-IV) scaled score&#xD;
A composit score will be calculated from the above tests and compared to the control group and normative data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index 3: Executive function</measure>
    <time_frame>Neuropsychological tests are performed immediately before or immediately after the MRI scan and scheduled to take 1½ hours.</time_frame>
    <description>Index 3 consist of the following tests&#xD;
Trail Making Test (D-KEFS) scaled score&#xD;
Verbal Fluency Test (D-KEFS) scaled score&#xD;
Color-Word Interference Test (D-KEFS) scaled score&#xD;
A composit score will be calculated from the above tests and compared to the control group and normative data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index 4: Verbal learning and memory</measure>
    <time_frame>Neuropsychological tests are performed immediately before or immediately after the MRI scan and scheduled to take 1½ hours.</time_frame>
    <description>Index 4 consist of the following tests&#xD;
Rey Auditory Verbal Learning Test (RAVLT) total learning scaled score&#xD;
Rey Auditory Verbal Learning Test (RAVLT) delayed recall scaled score&#xD;
A composit score will be calculated from the above tests and compared to the control group and normative data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index 5: Visual learning and memory</measure>
    <time_frame>Neuropsychological tests are performed immediately before or immediately after the MRI scan and scheduled to take 1½ hours.</time_frame>
    <description>Index 4 consist of the following tests&#xD;
Brief Visuospatial Memory Test-Revised (BVMT-R) total learning scaled score&#xD;
Brief Visuospatial Memory Test-Revised (BVMT-R) delayed recall scaled score&#xD;
A composit score will be calculated from the above tests and compared to the control group and normative data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of calcifications in the brain and cognitive function.</measure>
    <time_frame>The MRI scan: Baseline visit (duration 1 hr.). Neuropsychological tests are performed immediately before or immidiatly after the MRI.The analyses of the calcifications: Three months after the last subject has finished the study ( duration 1-2 mo)</time_frame>
    <description>Calcifications:&#xD;
The calcifications will be visually inspected on the PETRA sequense of the MRI scans.&#xD;
It will defined by its location (Globus pallidus, Thalamus, caudate nucleus, cortex, putamen, or cerebellum) and then defined in accordance with its size as listed below:&#xD;
The calcifications are going to be divided into 4 categories according to size:&#xD;
&quot;barely recognizable&quot; / up to approx. 1 mm,&#xD;
&quot;small&quot; / up to approx. 3 mm,&#xD;
&quot;medium&quot; / up to approx. 8 mm,&#xD;
&quot;large&quot; / approx. &gt; 8 mm. The size classification will be based on segmentation of the calcification finding the maximum cross section measured.&#xD;
The most severe score will be attributed if more than one calcification is present in one location.&#xD;
The calcifikation load of the patient will be an addition of scores from the different locations.&#xD;
There will be tested for a correlation of the calcification load and the scores from the Index 1, 2, 3, 4, and 5 of the neuropsychological tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in capillary transit time heterogeneity between patients and healthy controls</measure>
    <time_frame>MRI scan performed at baseline, no follow-up up. It takes 1 hour to perform</time_frame>
    <description>Capillary transit time heterogeneity is measured by MRI scans and compared between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Quality of Life between patients and healthy controls.</measure>
    <time_frame>The questionnaires were completed online within 3 weeks after the day with the MRI scand and the neurocognitive testing.</time_frame>
    <description>Quality of life is measured by three different questionnaires.&#xD;
36-Item Short Form Survey version 2 (SF36v2): A questionnaire with 36 questions on mental and physical complaints. The higher score, the better.&#xD;
: The WHO-5 wellbeing index: 5 questions on well being. The higher score the better.&#xD;
HPQ-28: A disease specific questionnaire designed for patients with Hypoparathyriodsm. The lower the score the better.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hypoparathyroidism</condition>
  <condition>Pseudo Hypoparathyroidism</condition>
  <arm_group>
    <arm_group_label>Postsurgical hypoparathyroidism</arm_group_label>
    <description>Patients with hypoparathyroidism for 3 or more years after neck surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-surgical hypoparathyroidism</arm_group_label>
    <description>Patients with hypoparathyroidism for 3 or more years without neck surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pseudohypoparathyroidism</arm_group_label>
    <description>Patients with the diagnosis of Pseudohypoparathyroidism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>25 controls from the background population matched on age (±3 years), gender and level of education with the 25 patients with postsurgical hypoparathyroidism</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI scans</intervention_name>
    <description>Contrast-enhanced, magnetic resonance imaging (MRI) based method to detect disturbances in microvascular flow patterns in the human brain</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Non-surgical hypoparathyroidism</arm_group_label>
    <arm_group_label>Postsurgical hypoparathyroidism</arm_group_label>
    <arm_group_label>Pseudohypoparathyroidism</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Neuro cognitive tests</intervention_name>
    <description>Standard neuropsychological test battery consists of validated tests to assess cognitive domains including verbal and visual memory, attention, language, visuospatial and executive functioning.</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Non-surgical hypoparathyroidism</arm_group_label>
    <arm_group_label>Postsurgical hypoparathyroidism</arm_group_label>
    <arm_group_label>Pseudohypoparathyroidism</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Questionnaires on Quality of Life</intervention_name>
    <description>SF36v2, WHO-5 well-being index, HPQ28, Symptom questionnaire, and a general questionnaire on background information, medication and diet.</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Non-surgical hypoparathyroidism</arm_group_label>
    <arm_group_label>Postsurgical hypoparathyroidism</arm_group_label>
    <arm_group_label>Pseudohypoparathyroidism</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Markers of calcium homeostasis, inflammatory markers and hematology.</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Non-surgical hypoparathyroidism</arm_group_label>
    <arm_group_label>Postsurgical hypoparathyroidism</arm_group_label>
    <arm_group_label>Pseudohypoparathyroidism</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>24 hr urine samples</intervention_name>
    <description>24 hr urine content of calcium, phosphate, magnesium, and creatinine.</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Non-surgical hypoparathyroidism</arm_group_label>
    <arm_group_label>Postsurgical hypoparathyroidism</arm_group_label>
    <arm_group_label>Pseudohypoparathyroidism</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum and 24hr urine samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patients with postsurgical, non-surgical and pseudo hypoparathyroidism will be invited&#xD;
        from our outpatient clinic to participate in the study.&#xD;
&#xD;
        The healthy controls will be randomly recruited from the background population by an&#xD;
        extract from the CPR register and an invitation to participate in the study will be send by&#xD;
        electronic letter.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients:&#xD;
&#xD;
          -  Male or female with age between 18 and 70 years.&#xD;
&#xD;
          -  A low endogenous PTH production as verified by low plasma levels of intact PTH,&#xD;
             necessitating treatment with 1-αhydroxylated vitamin D analogs.&#xD;
&#xD;
          -  HypoPT for 3 years with continuous alphacalcidol or calcitriol treatment prior to&#xD;
             study entry (except for the patients with PHP).&#xD;
&#xD;
          -  Stable P-calcium levels 1 month prior to inclusion.&#xD;
&#xD;
          -  In case of thyroid disease, TSH within reference range within the last year&#xD;
&#xD;
          -  Speaks and reads Danish&#xD;
&#xD;
        Controls:&#xD;
&#xD;
          -  Male or female with age between 18 and 80 years.&#xD;
&#xD;
          -  No known diseases in the calcium homeostasis&#xD;
&#xD;
          -  Speaks and reads Danish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Reduced kidney function (eGFR &lt; 30 mL/min/1.73m2).&#xD;
&#xD;
          -  Diabetes type 1 or 2&#xD;
&#xD;
          -  History of hypertension for more than two years (treated or untreated)&#xD;
&#xD;
          -  Clinical suspicion of major depression (also if treated)&#xD;
&#xD;
          -  Clinical suspicion of alcohol-related dementia&#xD;
&#xD;
          -  Other organic or psychiatric cause the patients symptoms&#xD;
&#xD;
          -  Contraindications to contrast-enhanced MRI.&#xD;
&#xD;
          -  Metal implants close to the head, which will interfere with the MRI or pacemaker. The&#xD;
             patients will complete a metal scheme.&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Unwillingness to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanja T Sikjær, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology and Internal Medicine, Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanja T Sikjaer, MD, PhD</last_name>
    <phone>0045 61711494</phone>
    <email>tanja.sikjaer@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars Rejnmark, PhD,D.M.Sc</last_name>
    <email>rejnmark@post6.tele.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinic for Osteoporosis, Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <state>Jutland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Sikjaer, MD,Ph.d st</last_name>
      <phone>+45 61711494</phone>
      <email>tanja.sikjaer@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Lars Rejnmark, MD, DrMed</last_name>
      <email>larsnien@rm.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Lars Rejnmark, PhD. DrMedSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tanja Sikjaer, MD Ph.D st.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Line Underbjerg, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res. 2013 Nov;28(11):2277-85. doi: 10.1002/jbmr.1979.</citation>
    <PMID>23661265</PMID>
  </reference>
  <reference>
    <citation>Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. The Epidemiology of Nonsurgical Hypoparathyroidism in Denmark: A Nationwide Case Finding Study. J Bone Miner Res. 2015 Sep;30(9):1738-44. doi: 10.1002/jbmr.2501. Epub 2015 May 31.</citation>
    <PMID>25753591</PMID>
  </reference>
  <reference>
    <citation>Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Pseudohypoparathyroidism - epidemiology, mortality and risk of complications. Clin Endocrinol (Oxf). 2016 Jun;84(6):904-11. doi: 10.1111/cen.12948. Epub 2015 Oct 19.</citation>
    <PMID>26387561</PMID>
  </reference>
  <reference>
    <citation>Bohrer T, Krannich JH. Depression as a manifestation of latent chronic hypoparathyroidism. World J Biol Psychiatry. 2007;8(1):56-9.</citation>
    <PMID>17366354</PMID>
  </reference>
  <reference>
    <citation>Lawlor BA. Hypocalcemia, hypoparathyroidism, and organic anxiety syndrome. J Clin Psychiatry. 1988 Aug;49(8):317-8. Review.</citation>
    <PMID>3045102</PMID>
  </reference>
  <reference>
    <citation>Snowdon JA, Macfie AC, Pearce JB. Hypocalcaemic myopathy with paranoid psychosis. J Neurol Neurosurg Psychiatry. 1976 Jan;39(1):48-52.</citation>
    <PMID>1255212</PMID>
  </reference>
  <reference>
    <citation>Arlt W, Fremerey C, Callies F, Reincke M, Schneider P, Timmermann W, Allolio B. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002 Feb;146(2):215-22.</citation>
    <PMID>11834431</PMID>
  </reference>
  <reference>
    <citation>Astor MC, Løvås K, Debowska A, Eriksen EF, Evang JA, Fossum C, Fougner KJ, Holte SE, Lima K, Moe RB, Myhre AG, Kemp EH, Nedrebø BG, Svartberg J, Husebye ES. Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway. J Clin Endocrinol Metab. 2016 Aug;101(8):3045-53. doi: 10.1210/jc.2016-1477. Epub 2016 May 17.</citation>
    <PMID>27186861</PMID>
  </reference>
  <reference>
    <citation>Sikjaer T, Moser E, Rolighed L, Underbjerg L, Bislev LS, Mosekilde L, Rejnmark L. Concurrent Hypoparathyroidism Is Associated With Impaired Physical Function and Quality of Life in Hypothyroidism. J Bone Miner Res. 2016 Jul;31(7):1440-8. doi: 10.1002/jbmr.2812. Epub 2016 Mar 31.</citation>
    <PMID>26865527</PMID>
  </reference>
  <reference>
    <citation>Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L. Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int. 2014 Jun;25(6):1717-26. doi: 10.1007/s00198-014-2677-6. Epub 2014 Apr 1.</citation>
    <PMID>24687385</PMID>
  </reference>
  <reference>
    <citation>Velasco PJ, Manshadi M, Breen K, Lippmann S. Psychiatric aspects of parathyroid disease. Psychosomatics. 1999 Nov-Dec;40(6):486-90. Review.</citation>
    <PMID>10581976</PMID>
  </reference>
  <reference>
    <citation>Underbjerg L, Sikjaer T, Rejnmark L. Health-related quality of life in patients with nonsurgical hypoparathyroidism and pseudohypoparathyroidism. Clin Endocrinol (Oxf). 2018 Jun;88(6):838-847. doi: 10.1111/cen.13593. Epub 2018 Apr 3.</citation>
    <PMID>29520810</PMID>
  </reference>
  <reference>
    <citation>Abiusi G, Domínguez RO, Parada Marcilla M, Lesyk S, Laguarde N, Yobstraibizer F. [Asymptomatic encephalic calcifications in postsurgical hypoparathyroidism]. Neurologia. 2009 Sep;24(7):454-6. Spanish.</citation>
    <PMID>19921554</PMID>
  </reference>
  <reference>
    <citation>Basak RC. A case report of Basal Ganglia calcification - a rare finding of hypoparathyroidism. Oman Med J. 2009 Jul;24(3):220-2. doi: 10.5001/omj.2009.44.</citation>
    <PMID>22224190</PMID>
  </reference>
  <reference>
    <citation>Bhimani S, Sarwar M, Virapongse C, Rojas R, Freilich M. Computed tomography of cerebrovascular calcifications in postsurgical hypoparathyroidism. J Comput Assist Tomogr. 1985 Jan-Feb;9(1):121-4.</citation>
    <PMID>3968258</PMID>
  </reference>
  <reference>
    <citation>Chow KS, Lu DN. [Primary hypoparathyroidism with basal ganglia calcification: report of a case]. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1989 Mar-Apr;30(2):129-33. Chinese.</citation>
    <PMID>2637591</PMID>
  </reference>
  <reference>
    <citation>DANOWSKI TS, LASSER EC, WECHSLER RL. Calcification of basal ganglia in post-thyroidectomy hypoparathyroidism. Metabolism. 1960 Nov;9:1064-5.</citation>
    <PMID>13719679</PMID>
  </reference>
  <reference>
    <citation>EATON, L. M. &amp; HAINES, S. F. Parathyroid insuffiency with symmetrical cerebral calcification. Journal of the American Medical Association 113, 749-753 (1939).</citation>
  </reference>
  <reference>
    <citation>Forman MB, Sandler MP, Danziger A, Kalk WJ. Basal ganglia calcification in postoperative hypoparathyroidism. Clin Endocrinol (Oxf). 1980 Apr;12(4):385-90.</citation>
    <PMID>7379319</PMID>
  </reference>
  <reference>
    <citation>Fukunaga M, Otsuka N, Ono S, Kajihara Y, Nishishita S, Nakano Y, Yamamoto I, Torizuka K, Morita R. Computed tomography of basal ganglia calcifications in pseudo- and idiopathic hypoparathyroidism. Radiat Med. 1987 Nov-Dec;5(6):187-90.</citation>
    <PMID>3452848</PMID>
  </reference>
  <reference>
    <citation>García Urra D, Barquero Jiménez MS, Varela de Seijas E, Rico Lenza H. [Calcification of the basal ganglia and hypoparathyroidism: Fahr disease. Study of a family]. Arch Neurobiol (Madr). 1990 Jan-Feb;53(1):18-22. Spanish.</citation>
    <PMID>2393337</PMID>
  </reference>
  <reference>
    <citation>Gonçalves Júnior JC, Oliveira TS, Arantes HP, Gonçalves FT, Fonseca AR, Jorge PT. [Cerebral calcifications due to hypoparathyroidism: considerations about cases diagnosed many years after partial thyroidectomy]. Arq Bras Endocrinol Metabol. 2006 Dec;50(6):1133-7. Portuguese. Erratum in: Arq Bras Endocrinol Metabol. 2007 Feb;51(1):147. João, C G 2nd [corrected to Gonçalves Júnior, João Carlos]; Torres, Fabrícia G [corrected to Gonçalves, Fabrícia Torres].</citation>
    <PMID>17221123</PMID>
  </reference>
  <reference>
    <citation>Jorens PG, Appel BJ, Hilte FA, Mahler C, De Deyn PP. Basal ganglia calcifications in postoperative hypoparathyroidism: a case with unusual characteristics. Acta Neurol Scand. 1991 Feb;83(2):137-40.</citation>
    <PMID>1902012</PMID>
  </reference>
  <reference>
    <citation>Jorgensen H, Vogt H. [Familial, idiopathic hypoparathyroidism with intracerebral calcifications and extrapyramidal symptoms]. Tidsskr Nor Laegeforen. 1977 May 30;97(15):771-4. Norwegian.</citation>
    <PMID>194354</PMID>
  </reference>
  <reference>
    <citation>Karimi M, Rasekhi AR, Rasekh M, Nabavizadeh SA, Assadsangabi R, Amirhakimi GH. Hypoparathyroidism and intracerebral calcification in patients with beta-thalassemia major. Eur J Radiol. 2009 Jun;70(3):481-4. doi: 10.1016/j.ejrad.2008.02.003. Epub 2008 Mar 25.</citation>
    <PMID>18367361</PMID>
  </reference>
  <reference>
    <citation>Mahmoodi M, De Sanctis V, Karimi M. Diffuse intracerebral calcification in a beta-thalassaemia major patient with hypoparathyroidism: a case report. Pediatr Endocrinol Rev. 2011 Mar;8 Suppl 2:331-3.</citation>
    <PMID>21705988</PMID>
  </reference>
  <reference>
    <citation>Kartin P, Zupevc M, Pogacnik T, Cerk M. Calcification of basal ganglia, postoperative hypoparathyroidism and extrapyramidal, cerebellar, pyramidal motor manifestations. J Neurol. 1982;227(3):171-6.</citation>
    <PMID>6181225</PMID>
  </reference>
  <reference>
    <citation>LEVIN P. Intracranial calcification associated with hypoparathyroidism. Bull N Y Acad Med. 1962 Sep;38:632-7.</citation>
    <PMID>14464573</PMID>
  </reference>
  <reference>
    <citation>Polverosi R, Zambelli C, Sbeghen R. [Calcification of the basal nuclei in hypoparathyroidism. The computed and magnetic resonance tomographic aspects]. Radiol Med. 1994 Jan-Feb;87(1-2):12-5. Italian.</citation>
    <PMID>8128014</PMID>
  </reference>
  <reference>
    <citation>Preusser M, Kitzwoegerer M, Budka H, Brugger S. Bilateral striopallidodentate calcification (Fahr's syndrome) and multiple system atrophy in a patient with longstanding hypoparathyroidism. Neuropathology. 2007 Oct;27(5):453-6.</citation>
    <PMID>18018479</PMID>
  </reference>
  <reference>
    <citation>Rastogi R, Beauchamp NJ, Ladenson PW. Calcification of the basal ganglia in chronic hypoparathyroidism. J Clin Endocrinol Metab. 2003 Apr;88(4):1476-7.</citation>
    <PMID>12679425</PMID>
  </reference>
  <reference>
    <citation>Stelmasiak Z, Tarach JS, Nowicka-Tarach BM, Mitosek-Szewczyk K, Drop A. Idiopathic hypoparathyroidism with intracranial calcifications and dominant skin manifestations. Med Sci Monit. 2000 Jan-Feb;6(1):145-50.</citation>
    <PMID>11208303</PMID>
  </reference>
  <reference>
    <citation>Levine MA. Pseudohypoparathyroidism: from bedside to bench and back. J Bone Miner Res. 1999 Aug;14(8):1255-60. Review.</citation>
    <PMID>10457257</PMID>
  </reference>
  <reference>
    <citation>Mantovani G, Bastepe M, Monk D, de Sanctis L, Thiele S, Usardi A, Ahmed SF, Bufo R, Choplin T, De Filippo G, Devernois G, Eggermann T, Elli FM, Freson K, García Ramirez A, Germain-Lee EL, Groussin L, Hamdy N, Hanna P, Hiort O, Jüppner H, Kamenický P, Knight N, Kottler ML, Le Norcy E, Lecumberri B, Levine MA, Mäkitie O, Martin R, Martos-Moreno GÁ, Minagawa M, Murray P, Pereda A, Pignolo R, Rejnmark L, Rodado R, Rothenbuhler A, Saraff V, Shoemaker AH, Shore EM, Silve C, Turan S, Woods P, Zillikens MC, Perez de Nanclares G, Linglart A. Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. Nat Rev Endocrinol. 2018 Aug;14(8):476-500. doi: 10.1038/s41574-018-0042-0. Review.</citation>
    <PMID>29959430</PMID>
  </reference>
  <reference>
    <citation>Jespersen SN, Østergaard L. The roles of cerebral blood flow, capillary transit time heterogeneity, and oxygen tension in brain oxygenation and metabolism. J Cereb Blood Flow Metab. 2012 Feb;32(2):264-77. doi: 10.1038/jcbfm.2011.153. Epub 2011 Nov 2.</citation>
    <PMID>22044867</PMID>
  </reference>
  <reference>
    <citation>Østergaard L, Jespersen SN, Mouridsen K, Mikkelsen IK, Jonsdottír KÝ, Tietze A, Blicher JU, Aamand R, Hjort N, Iversen NK, Cai C, Hougaard KD, Simonsen CZ, Von Weitzel-Mudersbach P, Modrau B, Nagenthiraja K, Riisgaard Ribe L, Hansen MB, Bekke SL, Dahlman MG, Puig J, Pedraza S, Serena J, Cho TH, Siemonsen S, Thomalla G, Fiehler J, Nighoghossian N, Andersen G. The role of the cerebral capillaries in acute ischemic stroke: the extended penumbra model. J Cereb Blood Flow Metab. 2013 May;33(5):635-48. doi: 10.1038/jcbfm.2013.18. Epub 2013 Feb 27. Review.</citation>
    <PMID>23443173</PMID>
  </reference>
  <reference>
    <citation>Betsholtz C, Keller A. PDGF, pericytes and the pathogenesis of idiopathic basal ganglia calcification (IBGC). Brain Pathol. 2014 Jul;24(4):387-95. doi: 10.1111/bpa.12158. Review.</citation>
    <PMID>24946076</PMID>
  </reference>
  <reference>
    <citation>Armulik A, Genové G, Mäe M, Nisancioglu MH, Wallgard E, Niaudet C, He L, Norlin J, Lindblom P, Strittmatter K, Johansson BR, Betsholtz C. Pericytes regulate the blood-brain barrier. Nature. 2010 Nov 25;468(7323):557-61. doi: 10.1038/nature09522. Epub 2010 Oct 13.</citation>
    <PMID>20944627</PMID>
  </reference>
  <reference>
    <citation>Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005 Sep 16;97(6):512-23. Review.</citation>
    <PMID>16166562</PMID>
  </reference>
  <reference>
    <citation>Hall CN, Reynell C, Gesslein B, Hamilton NB, Mishra A, Sutherland BA, O'Farrell FM, Buchan AM, Lauritzen M, Attwell D. Capillary pericytes regulate cerebral blood flow in health and disease. Nature. 2014 Apr 3;508(7494):55-60. doi: 10.1038/nature13165. Epub 2014 Mar 26.</citation>
    <PMID>24670647</PMID>
  </reference>
  <reference>
    <citation>Funk JL, Wei H, Downey KJ, Yocum D, Benjamin JB, Carley W. Expression of PTHrP and its cognate receptor in the rheumatoid synovial microcirculation. Biochem Biophys Res Commun. 2002 Oct 4;297(4):890-7.</citation>
    <PMID>12359237</PMID>
  </reference>
  <reference>
    <citation>Mouridsen K, Hansen MB, Østergaard L, Jespersen SN. Reliable estimation of capillary transit time distributions using DSC-MRI. J Cereb Blood Flow Metab. 2014 Sep;34(9):1511-21. doi: 10.1038/jcbfm.2014.111. Epub 2014 Jun 18.</citation>
    <PMID>24938401</PMID>
  </reference>
  <reference>
    <citation>Mouridsen K, Friston K, Hjort N, Gyldensted L, Østergaard L, Kiebel S. Bayesian estimation of cerebral perfusion using a physiological model of microvasculature. Neuroimage. 2006 Nov 1;33(2):570-9. Epub 2006 Sep 12.</citation>
    <PMID>16971140</PMID>
  </reference>
  <reference>
    <citation>Østergaard L, Jespersen SN, Engedahl T, Gutiérrez Jiménez E, Ashkanian M, Hansen MB, Eskildsen S, Mouridsen K. Capillary dysfunction: its detection and causative role in dementias and stroke. Curr Neurol Neurosci Rep. 2015 Jun;15(6):37. doi: 10.1007/s11910-015-0557-x. Review.</citation>
    <PMID>25956993</PMID>
  </reference>
  <reference>
    <citation>Eskildsen SF, Gyldensted L, Nagenthiraja K, Nielsen RB, Hansen MB, Dalby RB, Frandsen J, Rodell A, Gyldensted C, Jespersen SN, Lund TE, Mouridsen K, Brændgaard H, Østergaard L. Increased cortical capillary transit time heterogeneity in Alzheimer's disease: a DSC-MRI perfusion study. Neurobiol Aging. 2017 Feb;50:107-118. doi: 10.1016/j.neurobiolaging.2016.11.004. Epub 2016 Nov 19.</citation>
    <PMID>27951412</PMID>
  </reference>
  <reference>
    <citation>Nielsen RB, Egefjord L, Angleys H, Mouridsen K, Gejl M, Møller A, Brock B, Brændgaard H, Gottrup H, Rungby J, Eskildsen SF, Østergaard L. Capillary dysfunction is associated with symptom severity and neurodegeneration in Alzheimer's disease. Alzheimers Dement. 2017 Oct;13(10):1143-1153. doi: 10.1016/j.jalz.2017.02.007. Epub 2017 Mar 23.</citation>
    <PMID>28343848</PMID>
  </reference>
  <reference>
    <citation>Mouridsen K, Christensen S, Gyldensted L, Ostergaard L. Automatic selection of arterial input function using cluster analysis. Magn Reson Med. 2006 Mar;55(3):524-31.</citation>
    <PMID>16453314</PMID>
  </reference>
  <reference>
    <citation>Hansen B, Khan AR, Shemesh N, Lund TE, Sangill R, Eskildsen SF, Østergaard L, Jespersen SN. White matter biomarkers from fast protocols using axially symmetric diffusion kurtosis imaging. NMR Biomed. 2017 Sep;30(9). doi: 10.1002/nbm.3741. Epub 2017 May 22.</citation>
    <PMID>28543843</PMID>
  </reference>
  <reference>
    <citation>Hansen B, Lund TE, Sangill R, Jespersen SN. Experimentally and computationally fast method for estimation of a mean kurtosis. Magn Reson Med. 2013 Jun;69(6):1754-60. doi: 10.1002/mrm.24743. Epub 2013 Apr 15. Erratum in: Magn Reson Med. 2014 Jun;71(6):2250.</citation>
    <PMID>23589312</PMID>
  </reference>
  <reference>
    <citation>Hansen B, Shemesh N, Jespersen SN. Fast imaging of mean, axial and radial diffusion kurtosis. Neuroimage. 2016 Nov 15;142:381-393. doi: 10.1016/j.neuroimage.2016.08.022. Epub 2016 Aug 15.</citation>
    <PMID>27539807</PMID>
  </reference>
  <reference>
    <citation>Lewis, M. et al. Assessment of cognition in an adolescent Indigenous population. Australian Psychologist 45, 123-131, doi:10.1080/00050060903352998 (2010).</citation>
  </reference>
  <reference>
    <citation>Reitan, R. M. Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills 8 (1958).</citation>
  </reference>
  <reference>
    <citation>Wechsler, D. Wechsler Adult Intelligence Scale. Third edn, (The Psychological Corporation, 1997).</citation>
  </reference>
  <reference>
    <citation>Meyers, J. E. &amp; Meyers, K. R. Rey Complex Figure Test and Recognition Trail. (Psychological Assessment Resources, 1995).</citation>
  </reference>
  <reference>
    <citation>Nielsen H, Knudsen L, Daugbjerg O. Normative data for eight neuropsychological tests based on a Danish sample. Scand J Psychol. 1989;30(1):37-45.</citation>
    <PMID>2740854</PMID>
  </reference>
  <reference>
    <citation>Wilde D, Wilken L, Stamm B, Blaschke M, Heppner C, Chavanon ML, Leha A, Herrmann-Lingen C, Siggelkow H. The HPQ-Development and First Administration of a Questionnaire for Hypoparathyroid Patients. JBMR Plus. 2019 Nov 7;4(1):e10245. doi: 10.1002/jbm4.10245. eCollection 2020 Jan.</citation>
    <PMID>31956849</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 2, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Tanja Sikjær</investigator_full_name>
    <investigator_title>Principal Investigator, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Quality of Life</keyword>
  <keyword>MRI</keyword>
  <keyword>Cognitive Impairment</keyword>
  <keyword>Hypoparathyroidism</keyword>
  <keyword>Pseudohypoparathyroidism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudohypoparathyroidism</mesh_term>
    <mesh_term>Pseudopseudohypoparathyroidism</mesh_term>
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

